HCA Healthcare (NYSE:HCA) Announces Earnings Results

HCA Healthcare (NYSE:HCA) released its earnings results on Friday. The company reported $7.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.56 by $0.03, Briefing.com reports. The firm had revenue of $20.23 billion during the quarter, compared to analyst estimates of $19.76 billion. HCA Healthcare had a net margin of 8.89% and a negative return on equity of 295.93%. The business’s revenue was up 8.7% on a year-over-year basis. During the same period last year, the business earned $6.84 earnings per share.

Here are the key takeaways from HCA Healthcare’s conference call:

• HCA said the expiration of enhanced premium tax credits drove a bigger-than-expected payer mix shift, with exchange admissions down 15% and most of those patients moving almost one-for-one to uninsured.
• The company reported 11% diluted EPS growth in both the quarter and year to date, even as adjusted EBITDA was pressured by coverage losses and higher uncompensated care.
• Underlying demand remained solid, with ER visits up 3.6% and insured volumes excluding exchanges increasing, while HCA expects long-term demand growth of 2%-3% supported by population trends.
• Management highlighted over $7 billion of capital expenditures and continued network expansion, including new beds and outpatient facilities, as part of a strategy to grow capacity and market share.
• HCA updated full-year guidance to Adjusted EBITDA of $15.4 billion-$16.1 billion and said its resiliency program, cost discipline, and Medicaid supplemental payments should help offset some of the exchange headwind in the back half of 2026.

HCA Healthcare Stock Up 1.5%

Shares of NYSE HCA opened at $382.28 on Friday. The firm’s 50-day moving average price is $386.95 and its 200-day moving average price is $453.73. HCA Healthcare has a 52-week low of $330.00 and a 52-week high of $556.52. The company has a market cap of $84.80 billion, a PE ratio of 12.80, a PEG ratio of 1.29 and a beta of 1.12.

Hedge Funds Weigh In On HCA Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the company. Palisade Asset Management LLC bought a new stake in shares of HCA Healthcare in the third quarter worth $26,000. JPL Wealth Management LLC purchased a new stake in shares of HCA Healthcare during the 3rd quarter valued at about $33,000. Greenline Wealth Management LLC bought a new position in shares of HCA Healthcare in the 4th quarter worth approximately $42,000. EFG International AG bought a new stake in HCA Healthcare during the fourth quarter valued at approximately $44,000. Finally, Triumph Capital Management bought a new position in HCA Healthcare in the third quarter worth approximately $51,000. 62.73% of the stock is owned by institutional investors.

More HCA Healthcare News

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: HCA beat Q2 earnings estimates, reporting $7.59 per share versus expectations around $7.56-$7.57, while revenue rose 8.7% year over year to $20.23 billion and also topped estimates. HCA Healthcare earnings report
• Positive Sentiment: Management cited strong admissions and higher revenue per admission as key drivers of the quarter, suggesting healthy demand trends across its hospital network. Zacks article on HCA Q2 results
• Neutral Sentiment: HCA said its updated guidance is consistent with its earlier preview, so the quarter appears to confirm previously signaled results rather than deliver a major surprise. BusinessWire Q2 results
• Negative Sentiment: The company trimmed parts of its 2026 outlook, pointing to higher expenses and weaker surgical volumes as headwinds that could limit margin expansion. Zacks guidance revision article
• Negative Sentiment: Separate investor-law-firm investigations into HCA may add some legal overhang, though these notices are not operational results. Pomerantz investor alert

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HCA. Deutsche Bank Aktiengesellschaft lowered their price objective on HCA Healthcare from $558.00 to $540.00 and set a “buy” rating for the company in a research note on Tuesday, April 28th. Jefferies Financial Group set a $450.00 price target on HCA Healthcare in a research report on Tuesday, July 14th. Barclays cut their price objective on shares of HCA Healthcare from $427.00 to $402.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 16th. Robert W. Baird dropped their target price on shares of HCA Healthcare from $450.00 to $442.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Finally, KeyCorp decreased their price objective on shares of HCA Healthcare from $510.00 to $475.00 and set an “overweight” rating for the company in a report on Tuesday, July 14th. Fourteen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, HCA Healthcare currently has an average rating of “Moderate Buy” and an average price target of $483.45.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.